News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,566 Results
Type
Article (40199)
Company Profile (249)
Press Release (656118)
Section
Business (204416)
Career Advice (2030)
Deals (35506)
Drug Delivery (97)
Drug Development (81283)
Employer Resources (173)
FDA (16207)
Job Trends (14900)
News (345732)
Policy (32659)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2556)
Accelerated approval (3)
Adcomms (21)
Allergies (78)
Alliances (49448)
ALS (80)
Alzheimer's disease (1339)
Antibody-drug conjugate (ADC) (108)
Approvals (16193)
Artificial intelligence (222)
Autoimmune disease (14)
Automation (14)
Bankruptcy (361)
Best Places to Work (11659)
BIOSECURE Act (19)
Biosimilars (98)
Biotechnology (176)
Bladder cancer (57)
Brain cancer (24)
Breast cancer (247)
Cancer (1929)
Cardiovascular disease (151)
Career advice (1690)
Career pathing (29)
CAR-T (139)
Cell therapy (389)
Cervical cancer (16)
Clinical research (65728)
Collaboration (750)
Compensation (443)
Complete response letters (18)
COVID-19 (2691)
CRISPR (35)
C-suite (198)
Cystic fibrosis (97)
Data (1843)
Decentralized trials (2)
Denatured (15)
Depression (36)
Diabetes (240)
Diagnostics (6324)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (108)
Drug pricing (97)
Drug shortages (25)
Duchenne muscular dystrophy (82)
Earnings (86056)
Editorial (32)
Employer branding (22)
Employer resources (147)
Events (111547)
Executive appointments (627)
FDA (17260)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (676)
Gene editing (94)
Generative AI (18)
Gene therapy (274)
GLP-1 (682)
Government (4437)
Grass and pollen (4)
Guidances (48)
Healthcare (18830)
Huntington's disease (22)
IgA nephropathy (20)
Immunology and inflammation (102)
Indications (26)
Infectious disease (2822)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (79)
Interviews (314)
IPO (16492)
IRA (43)
Job creations (3667)
Job search strategy (1439)
Kidney cancer (9)
Labor market (33)
Layoffs (452)
Leadership (15)
Legal (7954)
Liver cancer (70)
Lung cancer (276)
Lymphoma (128)
Machine learning (2)
Management (58)
Manufacturing (265)
MASH (58)
Medical device (13305)
Medtech (13310)
Mergers & acquisitions (19469)
Metabolic disorders (622)
Multiple sclerosis (66)
NASH (16)
Neurodegenerative disease (72)
Neuropsychiatric disorders (24)
Neuroscience (1796)
NextGen: Class of 2025 (6526)
Non-profit (4481)
Northern California (2346)
Now hiring (36)
Obesity (338)
Opinion (208)
Ovarian cancer (70)
Pain (75)
Pancreatic cancer (75)
Parkinson's disease (127)
Partnered (18)
Patents (200)
Patient recruitment (90)
Peanut (45)
People (57167)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20468)
Phase II (28940)
Phase III (21602)
Pipeline (904)
Podcasts (59)
Policy (113)
Postmarket research (2569)
Preclinical (8637)
Press Release (64)
Prostate cancer (91)
Psychedelics (33)
Radiopharmaceuticals (243)
Rare diseases (351)
Real estate (5915)
Recruiting (66)
Regulatory (22144)
Reports (46)
Research institute (2322)
Resumes & cover letters (353)
Rett syndrome (3)
RNA editing (2)
RSV (43)
Schizophrenia (62)
Series A (119)
Series B (75)
Service/supplier (11)
Sickle cell disease (50)
Southern California (2021)
Special edition (15)
Spinal muscular atrophy (146)
Sponsored (28)
Startups (3592)
State (2)
Stomach cancer (12)
Supply chain (61)
The Weekly (42)
United States (20593)
Vaccines (706)
Venture capitalists (37)
Webinars (12)
Weight loss (229)
Women's health (32)
Worklife (15)
Date
Today (122)
Last 7 days (568)
Last 30 days (2855)
Last 365 days (33785)
2025 (7290)
2024 (35296)
2023 (40146)
2022 (51239)
2021 (55816)
2020 (54167)
2019 (46585)
2018 (35076)
2017 (32217)
2016 (31595)
2015 (37612)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (725)
Alabama (49)
Alaska (7)
Arizona (221)
Arkansas (13)
Asia (37764)
Australia (6168)
California (5363)
Canada (1842)
China (451)
Colorado (239)
Connecticut (256)
Delaware (123)
Europe (81009)
Florida (796)
Georgia (187)
Idaho (57)
Illinois (482)
India (22)
Indiana (285)
Iowa (8)
Japan (134)
Kansas (99)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (813)
Massachusetts (4050)
Michigan (208)
Minnesota (366)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (55)
New Hampshire (62)
New Jersey (1520)
New Mexico (28)
New York (1550)
North Carolina (898)
North Dakota (7)
Northern California (2346)
Ohio (190)
Oklahoma (14)
Oregon (33)
Pennsylvania (1216)
Puerto Rico (9)
Rhode Island (25)
South America (1100)
South Carolina (17)
South Dakota (1)
Southern California (2021)
Tennessee (92)
Texas (794)
Utah (162)
Virginia (126)
Washington D.C. (57)
Washington State (505)
West Virginia (3)
Wisconsin (48)
696,566 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Cancer
Pfizer Sees Path to Braftovi’s Full Approval With Phase III CRC Data
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the way for its full approval for the treatment of certain colorectal cancers, according to the company.
February 3, 2025
·
2 min read
·
Tristan Manalac
Approvals
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate cancer, while recent readouts also position the pharma as a strong contender in colorectal cancer and bladder cancer.
February 13, 2025
·
2 min read
·
Tristan Manalac
Vaccines
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
January 8, 2025
·
2 min read
·
Tristan Manalac
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.
December 12, 2024
·
1 min read
·
Annalee Armstrong
Gene therapy
Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
February 21, 2025
·
2 min read
·
Tristan Manalac
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.
December 12, 2024
·
2 min read
·
Tristan Manalac
Cancer
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of metastatic colorectal cancer.
January 27, 2025
·
2 min read
·
Tristan Manalac
Earnings
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
February 4, 2025
·
4 min read
·
Annalee Armstrong
1 of 69,657
Next
